Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 20/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763520 | 0.93 | SLC9A1 (0.56) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL7991213 | 0.92 | SLC9A1 (0.52) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1763336 | 0.91 | SLC9A1 (0.61) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL12593498 | 0.89 | SLC9A1 (0.46) | SLC9A1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1763649 | 0.89 | SLC9A1 (0.61) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1763573 | 0.89 | SLC9A1 (0.59) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1764231 | 0.89 | SLC9A1 (0.49) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1763606 | 0.87 | SLC9A1 (0.69) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1763792 | 0.86 | SLC9A1 (0.60) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 | |
| SCHEMBL1763300 | 0.86 | SLC9A1 (0.68) | SLC9A1CYP2C9CYP2C19CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885CYP2C9 1660/4885CYP2C19 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.